Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy

J Hepatol. 2022 Sep;77(3):593-595. doi: 10.1016/j.jhep.2022.05.038. Epub 2022 Jun 15.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Carcinoma, Hepatocellular*
  • Humans
  • Immunotherapy
  • Liver Neoplasms*
  • Metformin* / pharmacology
  • Metformin* / therapeutic use
  • Non-alcoholic Fatty Liver Disease* / therapy

Substances

  • Metformin